APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
Primer: Chugai Pharmaceutical (4519 JT) - Aug 2026
Chugai's unique strategic alliance with Roche forms the cornerstone of its business model, providing a wide economic moat. This relationship...
96 Views
Primer: Chugai Pharmaceutical (4519 JP) - Aug 2026
Chugai's unique business model, a strategic alliance with Roche, provides a stable revenue base in Japan and a global platform for its...
100 Views
Chugai Pharma (4519 JP): Guidance Reiterated As Both Overseas & Domestic Grow in 1H26
Chugai Pharma (4519 JP) reports growth in both domestic and overseas markets in 1H26. 2026 guidance reiterated. Hemlibra export still key but new...
134 Views
EQD | Nikkei 225 Option Opportunity – Earn Premium in Sideways Markets with Straddles
Investors can earn a premium by using a short straddle strategy on the Nikkei 225, which has been trading sideways for the past eleven weeks.
412 Views